MicroRNAs in Cardiac Hypertrophy

MicroRNAs in Cardiac Hypertrophy

Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac hypertrophy, with age. This remodeling, however, is intensified under stress and pathological conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal cardiac output in times...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences Vol. 20; no. 19; p. 4714
Main Authors: Wehbe, Nadine, Nasser, Suzanne Awani, Pintus, Gianfranco, Badran, Adnan, Eid, Ali H, Baydoun, Elias
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 23-09-2019
MDPI
Subjects:
Animals
Biopsy
cardiac hypertrophy
Cardiac output
cardiac remodeling
Cardiomegaly - metabolism
Cardiomegaly - pathology
cardiomyocyte
Cardiomyocytes
Cell cycle
Cell division
Congestive heart failure
Gene expression
Genes
Heart attacks
Heart Failure - metabolism
Heart Failure - pathology
Humans
Hypertrophy
Insulin-like growth factors
Kinases
MicroRNAs
MicroRNAs - metabolism
miRNA
Organs
Physiology
Protein expression
Proteins
Review
Signal Transduction
therapeutic targets
Transcription factors
therapeutic targets
cardiac hypertrophy
MicroRNAs
cardiac remodeling
cardiomyocyte
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac hypertrophy, with age. This remodeling, however, is intensified under stress and pathological conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal cardiac output in times of need; however, chronic cardiac hypertrophy may lead to heart failure and death. MicroRNAs (miRNAs) are known to have a role in the regulation of cardiac hypertrophy. This paper reviews recent advances in the field of miRNAs and cardiac hypertrophy, highlighting the latest findings for targeted genes and involved signaling pathways. By targeting pro-hypertrophic genes and signaling pathways, some of these miRNAs alleviate cardiac hypertrophy, while others enhance it. Therefore, miRNAs represent very promising potential pharmacotherapeutic targets for the management and treatment of cardiac hypertrophy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20194714